|
1
|
Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts.
|
Hepatology
|
2011
|
2.33
|
|
2
|
Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
|
Int J Cancer
|
2004
|
1.76
|
|
3
|
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
|
Hepatology
|
2009
|
1.74
|
|
4
|
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
|
Hepatology
|
2008
|
1.73
|
|
5
|
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
|
Hepatology
|
2009
|
1.27
|
|
6
|
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
|
Hepatology
|
2010
|
1.26
|
|
7
|
Inhibiting TGF-β signaling in hepatocellular carcinoma.
|
Biochim Biophys Acta
|
2010
|
1.20
|
|
8
|
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin.
|
Am J Pathol
|
2002
|
1.17
|
|
9
|
Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients.
|
Clin Chim Acta
|
2007
|
1.14
|
|
10
|
SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC.
|
Int J Cancer
|
2005
|
1.11
|
|
11
|
Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C.
|
Intervirology
|
2010
|
1.08
|
|
12
|
Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.
|
Int J Cancer
|
2002
|
1.05
|
|
13
|
Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma.
|
Clin Cancer Res
|
2003
|
1.04
|
|
14
|
Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma.
|
Int J Cancer
|
2005
|
1.01
|
|
15
|
Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins.
|
Ageing Res Rev
|
2006
|
1.00
|
|
16
|
TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1α-driven human polyclonal B-cell activation.
|
Acta Trop
|
2011
|
0.99
|
|
17
|
Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion.
|
Clin Exp Metastasis
|
2002
|
0.97
|
|
18
|
APC-dependent impairment of T cell proliferation in aging: role of CD28- and IL-12/IL-15-mediated signaling.
|
Mech Ageing Dev
|
2002
|
0.96
|
|
19
|
Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins.
|
Hepatology
|
2007
|
0.95
|
|
20
|
Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases.
|
Hepatol Res
|
2002
|
0.94
|
|
21
|
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.
|
J Clin Gastroenterol
|
2006
|
0.90
|
|
22
|
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.
|
Clin Dev Immunol
|
2011
|
0.89
|
|
23
|
[An unusual case of transient loss of consciousness: the Fahr's syndrome].
|
Recenti Prog Med
|
2008
|
0.89
|
|
24
|
Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC.
|
Mol Cancer
|
2009
|
0.88
|
|
25
|
Hepatic stellate cells stimulate HCC cell migration via laminin-5 production.
|
Clin Sci (Lond)
|
2011
|
0.88
|
|
26
|
HCC heterogeneity: molecular pathogenesis and clinical implications.
|
Cell Oncol
|
2009
|
0.87
|
|
27
|
Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes.
|
J Interferon Cytokine Res
|
2006
|
0.87
|
|
28
|
Gelatinase expression at positive patch test reactions.
|
Contact Dermatitis
|
2002
|
0.86
|
|
29
|
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.
|
Biochem Pharmacol
|
2005
|
0.85
|
|
30
|
MxA and PKR expression in chronic hepatitis C.
|
J Interferon Cytokine Res
|
2004
|
0.85
|
|
31
|
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
|
Curr Med Res Opin
|
2005
|
0.84
|
|
32
|
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
|
Cancer Chemother Pharmacol
|
2010
|
0.84
|
|
33
|
Case of multiple myeloma mimicking an infectious disease with fever, intrahepatic cholestasis, renal failure, and pulmonary insufficiency.
|
Am J Hematol
|
2003
|
0.84
|
|
34
|
Role of phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways in granulocyte macrophage-colony-stimulating factor failure to delay fas-induced neutrophil apoptosis in elderly humans.
|
J Gerontol A Biol Sci Med Sci
|
2006
|
0.84
|
|
35
|
PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.
|
Int J Cancer
|
2012
|
0.83
|
|
36
|
Impaired interleukin-12-dependent T-cell functions during aging: role of signal transducer and activator of transcription 4 (STAT4) and suppressor of cytokine signaling 3 (SOCS3).
|
J Gerontol A Biol Sci Med Sci
|
2006
|
0.83
|
|
37
|
Gelatinase levels in male and female breast cancer.
|
Biochem Biophys Res Commun
|
2002
|
0.82
|
|
38
|
The TGF-β signaling pathway as a pharmacological target in a hepatocellular carcinoma.
|
Curr Pharm Des
|
2012
|
0.81
|
|
39
|
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
|
New Microbiol
|
2005
|
0.81
|
|
40
|
Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?
|
Biochim Biophys Acta
|
2010
|
0.81
|
|
41
|
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy.
|
J Clin Immunol
|
2010
|
0.80
|
|
42
|
Palmodigital purpura as the only skin abnormality in myeloma-associated systemic amyloidosis.
|
Br J Haematol
|
2003
|
0.80
|
|
43
|
EGFR and VEGFR as potential target for biological therapies in HCC cells.
|
Cancer Lett
|
2008
|
0.80
|
|
44
|
Role of defective ERK phosphorylation in the impaired GM-CSF-induced oxidative response of neutrophils in elderly humans.
|
Mech Ageing Dev
|
2004
|
0.78
|
|
45
|
[Syndrome of overlap: Chronic hepatitis C/autoimmune hepatitis: fact or fancy?].
|
Recenti Prog Med
|
2005
|
0.77
|
|
46
|
Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin.
|
J Interferon Cytokine Res
|
2005
|
0.77
|
|
47
|
Asymptomatic systemic sarcoidosis arising 5 years after IFN-alpha treatment for chronic hepatitis C: a new challenge for clinicians.
|
J Interferon Cytokine Res
|
2004
|
0.76
|
|
48
|
[Chronic hepatitis C/autoimmune hepatitis overlap syndrome: report of two cases].
|
Recenti Prog Med
|
2004
|
0.75
|
|
49
|
Proteolytic balance in patients with multiple sclerosis during interferon treatment.
|
J Interferon Cytokine Res
|
2002
|
0.75
|
|
50
|
Treatment of community-acquired pneumonia: a descriptive study in an Apulian department of internal medicine.
|
Med Sci Monit
|
2005
|
0.75
|
|
51
|
[Diarrhea as first clinical manifestation of hepatocellular carcinoma].
|
Recenti Prog Med
|
2002
|
0.75
|
|
52
|
[Multiple extrahepatic manifestations in a patient with chronic hepatitis C treated with interferon-alfa].
|
Recenti Prog Med
|
2004
|
0.75
|
|
53
|
[Hepatocellular carcinoma: tumoral or peritumoral disease?].
|
Recenti Prog Med
|
2007
|
0.75
|
|
54
|
[Clarkson syndrome: a rare clinical condition characterized by generalized edema associated to monoclonal gammopathy].
|
Recenti Prog Med
|
2005
|
0.75
|
|
55
|
[Extrapulmonary sarcoidosis with prevalent liver involvement: a new case and review of the literature].
|
Recenti Prog Med
|
2006
|
0.75
|
|
56
|
Glaucoma in primary amyloidosis: a fortuitous or causative association?
|
Am J Med
|
2002
|
0.75
|